334 articles with Orexo AB
Orexo AB, announces that the US Patent and Trademark Office has issued another two patents relating to ZUBSOLV®, Orexo's sublingual buprenorphine and naloxone tablet for the treatment of opioid use disorder.
A partnership agreement was reached with Magellan Rx, the third largest payor for treatment of opioid dependence in the US, to test modia™ with patients and other payors in their network
The Covid-19 pandemic has highlighted the urgent need for additional resources to prevent overdose deaths, which have reached an all-time high with an increase of 21 percent1
Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) ") has today given notice to all holders of the Company's maximum SEK 500,000,000 senior unsecured callable floating rate bonds 2017/2021 with ISIN SE0010494450 (the "Bonds") of exercise of its option for early redemption of the Bonds in full. The date
Orexo AB, has mandated ABG Sundal Collier AB to arrange a series of fixed income investor meetings in the Nordics, commencing on 1 February 2021.
Finalized the technical development of modia™, a digital therapy for opioid use disorder, for which Orexo owns the exclusive global rights
Previous human pharmacokinetic (PK) study showed significantly better PK profile when compared to market leading product
Orexo AB, announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®, Orexo's sublingual buprenorphine and naloxone tablet for the treatment of opioid use disorder.
Orexo AB, has entered into an exclusive licensing agreement with Accord Healthcare, for the commercialisation of ZUBSOLV® and naloxone ) sublingual tablet.
In connection with the publication of the Interim Report for Q3 2020, an updated guiding was shared for the full year 2020.
Net earnings of SEK -84.9 m (111.7), net earnings of SEK -22.4 m excluding DTx launch. Net earnings also impacted by a material one-time tax adjustment of SEK -43.5 m.
Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced that Rohan Dixit of Lief Therapeutics was chosen as the winner of the Lyfebulb and Orexo Innovation Challenge: Solutions for Substance Use Disorders. Lief T
- Prior to the Annual General Meeting (AGM) in 2021, Orexo has appointed a Nomination Committee which represents approximately 44 percent of the number of votes in the company as of September 30, 2020 . The Nomination Committee, comprises: Christian Salling , Novo Holdings A/S, also Chairman of the Nomination Committee
Orexo AB, invites investors, analysts, and media to attend a teleconference on Thursday October 1, at 3 pm CET.
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has filed a patent infringement action in the United States District Court for the District of New Jersey with docket number 3:20-cv-12588, against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Indu
Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders
The Challenge recognizes Patient Entrepreneurs with solutions that aid successful, long-term recovery from alcohol and opioid use disorders [01-September-2020] UPPSALA, Sweden and NEW YORK , Sept. 1, 2020 /PRNewswire/ -- Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, an
Orexo AB, announces it has received a "paragraph IV" patent certification notice from Sun Pharmaceutical Industries Limited.
US launch of the scientifically proven digital therapies deprexis® July 1 and forthcoming launch of vorvida® July 20
FDA's "Enforcement Policy" and Orexo's strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies
Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal
Orexo AB, announces positive results from its human pharmacokinetic study of OX125.